Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell & Gene Therapy Asia 2019

Ryuichi Morishita's Biography

Ryuichi Morishita, Professor of Clinical Gene Therapy, Osaka University School of Medicine

Ryuichi Morishita, M.D., Ph.D., graduated Osaka University Medical School in 1987, and received Ph. D. from Osaka University in 1991. After following postdoctoral Fellow at Stanford University School of Medicine, he served as an Assistant Professor, Department of Geriatric Medicine, Osaka University Medical School from 1994 to 1998. Then, from 1998 to 2003, he was Associate Professor, Division of Gene Therapy Science, Osaka University Medical School. Then, he became Professor & Chairman of Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University Medical School from 2003.

Professor Morishita received over 20 awards from various academic societies including Harry Goldbratt Award in Council of High Blood Pressure, American Heart Association, Award in Japanese of Japan Medical Society, Sato Award in 27th annual meeting of the Japanese Circulation Society and Invitrogen-Nature-Biotechnology Award.

Professor Morishita is currently on the editorial board of over 30 scientific journals including Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry (Editor-in-Chief), Gene Therapy, ATVB, Circulation and Hypertension. He has published over 400 original articles and review papers, primarily on gene therapy and molecular biology in cardiovascular disease. In addition, Professor Morishita is a Board Member of numerous medical organizations, including Japanese Society of Gene Therapy, Japan Society of Vascular Medicine, Japanese Society of Anti-aging and others.

He is currently member of Committee for Regulation Reform (Advisor Committee of Shinzo Abe Prime Minister of Japan), and Strategic Advisor of Headquarter for HealthCare Strategy (Chief is Shizo Abe, Prime Minister of Japan). He is also Special Advisor of Osaka Prefecture and Osaka City. He also worked as a member of Intellectual Property Committee of Koizumi & Abe Cabinet. His professional activities & appointments include Committee for Industry-Academia Relationship, Ministry of Education, Science and Culture of Japan, Vice Chairman, Bio-Venture Association Originated from Universities, and others.

Ryuichi Morishita Image

First Commercial Available Gene Therapy Drug “Collategen” in Cardiovascular Disease

Monday, 11 November 2019 at 11:30

Add to Calendar ▼2019-11-11 11:30:002019-11-11 12:30:00Europe/LondonFirst Commercial Available Gene Therapy Drug “Collategen” in Cardiovascular DiseaseCell and Gene Therapy Asia 2019 in Kobe, JapanKobe,

Gene therapy has emerged as a novel therapy to promote angiogenesis in patients with critical limb ischemia (CLI) caused by peripheral artery disease. We have focused on hepatocyte growth factor (HGF) as pro-angiogenic factors. In the clinical trials of phase III, the naked plasmid DNA encoding HGF showed the safety and their potential for symptomatic improvement in CLI patients. Improvement rate was 70.4 % in HGF and 30.8% in placebo in Fontaine III patients (P=0.014). HGF gene therapy achieved a significantly higher improvement rate of ischemic ulcers compared with placebo (100% vs. 40%, P=0.018). No major safety problems were observed. Based on phase III data, in this year, HGF will be launched in Japan market as the first gene therapy drug.

Add to Calendar ▼2019-11-11 00:00:002019-11-12 00:00:00Europe/LondonCell and Gene Therapy Asia 2019Cell and Gene Therapy Asia 2019 in Kobe, JapanKobe,